Literature DB >> 8034567

Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors.

L DaSilva1, O M Howard, H Rui, R A Kirken, W L Farrar.   

Abstract

Prolactin (PRL) has recently been demonstrated to induce tyrosine phosphorylation and activation of the cytoplasmic tyrosine kinase JAK2 in PRL-dependent Nb2 lymphoma cells. The present study represents an initial effort to identify cytoplasmic regions of the PRL receptor (PRLR) that are critical to growth signal generation and JAK2 activation. Variably truncated rat PRLRs were stably expressed in the murine 32D cell line. PRL-induced proliferation was mediated by the full-length receptor and the mutant G328, which contains the membrane-proximal Homology Boxes 1 and 2 characteristic of hematopoietin receptors. In contrast, mutant receptors lacking either Box 2 or both Boxes 1 and 2 were not capable of transmitting a growth signal. The mitogenic capacity of the PRLR variants correlated with JAK2 association and activation, as well as with induction of mRNA levels for the growth-related gene ornithine decarboxylase. We conclude that mitogenic competence of rat PRLRs resides within the first 94 amino acids of the cytoplasmic domain. The data suggest that Homology Box 1/Box 2 region is critical to JAK2 phosphorylation and association with the PRLR. These findings will serve as a basis for more detailed molecular characterization of PRLR domains essential for JAK2 interaction and growth signal generation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8034567

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Modulation of growth factor receptor function by isoform heterodimerization.

Authors:  W P Chang; C V Clevenger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Structural domains of interleukin-2 receptor beta critical for signal transduction: kinase association and nuclear complex-formation.

Authors:  O M Howard; R A Kirken; G G Garcia; R H Hackett; W L Farrar
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

3.  Expression of xanthine oxidoreductase in mouse mammary epithelium during pregnancy and lactation: regulation of gene expression by glucocorticoids and prolactin.

Authors:  M Kurosaki; S Zanotta; M Li Calzi; E Garattini; M Terao
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

4.  Identification of NEK3 Kinase Threonine 165 as a Novel Regulatory Phosphorylation Site That Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration.

Authors:  Katherine M Harrington; Charles V Clevenger
Journal:  J Biol Chem       Date:  2016-08-03       Impact factor: 5.157

5.  Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer.

Authors:  Yunfei Wen; Ying Wang; Anca Chelariu-Raicu; Elaine Stur; Yuan Liu; Sara Corvigno; Faith Bartsch; Lauren Redfern; Behrouz Zand; Yu Kang; Jinsong Liu; Keith Baggerly; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2020-07-31       Impact factor: 6.261

6.  Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports.

Authors:  Senthil K Muthuswamy
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

7.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

8.  Prolactin regulates ZNT2 expression through the JAK2/STAT5 signaling pathway in mammary cells.

Authors:  Linxi Qian; Veronica Lopez; Young Ah Seo; Shannon L Kelleher
Journal:  Am J Physiol Cell Physiol       Date:  2009-06-03       Impact factor: 4.249

9.  Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation.

Authors:  Fabien Van Coppenolle; Roman Skryma; Halima Ouadid-Ahidouch; Christian Slomianny; Morad Roudbaraki; Philippe Delcourt; Etienne Dewailly; Sandrine Humez; Alexandre Crépin; Isabelle Gourdou; Jean Djiane; Jean-Louis Bonnal; Brigitte Mauroy; Natalia Prevarskaya
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

10.  Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

Authors:  Anas Younes; Jorge Romaguera; Michelle Fanale; Peter McLaughlin; Frederick Hagemeister; Amanda Copeland; Sattva Neelapu; Larry Kwak; Jatin Shah; Silvana de Castro Faria; Stefan Hart; Jeanette Wood; Ramesh Jayaraman; Kantharaj Ethirajulu; Joy Zhu
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.